Literature DB >> 10160112

Pharmacoeconomics and formulary decision making.

L A Sanchez1.   

Abstract

Pharmacoeconomic assessment of formulary actions has become increasingly common in local, national, and international formulary decision making. Tactics for managing medication use include formulary management and drug policies. Pharmacoeconomic data can provide support for these formulary decisions. For example, pharmacoeconomic data can support the inclusion or exclusion of a drug on or from the formulary and support practice guidelines that promote the most cost-effective or appropriate utilisation of pharmaceutical products. Various strategies can be used to incorporate pharmacoeconomics into formulary decision making. These include using published pharmacoeconomic studies and economic modelling techniques, and conducting local pharmacoeconomic research. Criteria for evaluating the pharmacoeconomic literature, suggestions for employing economic models, and suggested guidelines for conducting pharmacoeconomic projects are discussed. Although most formularies are viewed as cost-containment tools, formularies should not be a list of the 'cheapest' alternatives. Today's formulary should contain agents that optimise therapeutic outcomes while controlling cost. Pharmacoeconomic assessments of formulary decisions help to ensure that the agents promoted by our formularies yield the highest outcome per dollar spent. A discussion of the process for formulary action in a US hospital, the influence of pharmacoeconomics on US formularies, and strategies for incorporating pharmacoeconomics into formulary decision making are presented in this paper.

Mesh:

Year:  1996        PMID: 10160112     DOI: 10.2165/00019053-199600091-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  25 in total

Review 1.  Expanding the role of pharmacists in pharmacoeconomics: why and how?

Authors:  L A Sanchez
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

2.  Evaluation of the pharmacoeconomic literature.

Authors:  R J Milne
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

3.  Evaluating the quality of published pharmacoeconomic evaluations.

Authors:  L A Sanchez
Journal:  Hosp Pharm       Date:  1995-02

4.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

5.  Guidelines for pharmacoeconomic studies.

Authors:  W F McGhan; N J Lewis
Journal:  Clin Ther       Date:  1992 May-Jun       Impact factor: 3.393

Review 6.  Interpretation of "cost-effective" and soundness of economic evaluations in the pharmacy literature.

Authors:  J T Lee; L A Sanchez
Journal:  Am J Hosp Pharm       Date:  1991-12

7.  Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology.

Authors: 
Journal:  Ann Intern Med       Date:  1995-07-01       Impact factor: 25.391

Review 8.  Evaluation of pharmacoeconomic studies: utilization of a checklist.

Authors:  J A Sacristán; J Soto; I Galende
Journal:  Ann Pharmacother       Date:  1993-09       Impact factor: 3.154

9.  Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research.

Authors:  C M Kozma; C E Reeder; R M Schulz
Journal:  Clin Ther       Date:  1993 Nov-Dec       Impact factor: 3.393

10.  Formulary evaluation of second-generation cephamycin derivatives using decision analysis.

Authors:  S L Barriere
Journal:  Am J Hosp Pharm       Date:  1991-10
View more
  3 in total

1.  Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making.

Authors:  C Daniel Mullins; Junling Wang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 2.  The effect of managed care on prescription drug costs and benefits.

Authors:  A Lyles; F B Palumbo
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

Review 3.  Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review.

Authors:  Amani Thomas Mori; Bjarne Robberstad
Journal:  BMC Med Inform Decis Mak       Date:  2012-09-27       Impact factor: 2.796

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.